Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 48 clinical trials
featured
Myelofibrosis

Myelofibrosis

  • 532 views
  • 08 Nov, 2020
  • 1 location
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.

hydroxyurea
neutrophil count
interferon
platelet count
anagrelide
  • 0 views
  • 20 Mar, 2021
  • 51 locations
IMG-7289 in Patients With Essential Thrombocythemia

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with essential thrombocythemia. This study investigates the following:

interferon
thrombosis
thrombocytosis
platelet count
  • 0 views
  • 06 Mar, 2021
  • 1 location
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

This study is to evaluate the efficacy and safety according to incremental dosing for 8 weeks and duration of administration for 1 year in patients with high-risk essential thrombocythemia.

platelet count
thrombocytosis
  • 7 views
  • 24 Jan, 2021
  • 14 locations
Hematology IMG-7289 LSD1 (Lysine-Specific Demethylase 1) Inhibitor Essential Thrombocythemia (ET) Ph 2

This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

hydroxyurea
neutrophil count
interferon
myelofibrosis
platelet count
  • 0 views
  • 24 Jan, 2021
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia

Objectives: To compare the efficacy and safety in children (<18 years) diagnosed as essential thrombocythemia treated with the Pegylated Interferon Alfa-2b vs. Interferon Alfa. Study

  • 0 views
  • 24 Jan, 2021
  • 1 location
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

ratio of aspirin maintenance in high risk Essential thrombocythemia (ET) patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea.

hydroxyurea
essential thrombocythemia
thrombosis
thrombocytosis
aspirin
  • 1 views
  • 21 Jan, 2021
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib

neutrophil count
conjugated bilirubin
essential thrombocythemia
thrombocythemia
pacritinib
  • 506 views
  • 09 May, 2021
  • 176 locations
IMG-7289 in Patients With Myelofibrosis

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis. This study investigates the following: The safety and tolerability of IMG-7289 The pharmacokinetics of IMG-7289 (performed in Phase 1/2a only) The pharmacodynamic effect of IMG-7289

  • 478 views
  • 27 Feb, 2021
  • 5 locations
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

  • 0 views
  • 01 May, 2021
  • 130 locations